WitrynaAt ESMO Congress 2024, results from three phase III trials evaluating the use of adjuvant immunotherapy in renal cell carcinoma (RCC) show no improvements in disease-free survival (DFS) in patients enrolled, opening up new questions on the future of immunotherapy in this setting. In the first study, the IMmotion010 phase III trial, the … Witryna10 wrz 2024 · IMmotion010 is a randomised, double-blind, multicentre, phase 3 trial conducted in 215 centres in 28 countries. Eligible patients were patients aged 18 …
アテゾリズマブ術後補助療法、PD-L1 TC≧1% Stage II~IIIA …
Witryna27 lip 2024 · This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy . How does the IMmotion010 clinical trial work? This clinical trial is recruiting people … Witryna19 paź 2024 · IMmotion010是一项随机、双盲、多中心、3期研究,旨在评估阿替利珠单抗对比安慰剂用于中/高复发风险的肾细胞癌(含透明细胞或肉瘤样特征成分)患者术 … birdland weather report live
A phase III study of atezolizumab (atezo) vs placebo as adjuvant ...
Witryna7 paź 2024 · IMmotion010研究是一项随机、双盲、安慰剂对照的III期临床试验,旨在评估Tecentriq用于手术切除后高复发风险的肾细胞癌患者的辅助治疗的疗效。此次失利也让Tecentriq与Keytruda在肾癌领域的交锋中拉开差距。 Witryna1 paź 2024 · Methods: IMmotion010 is a randomised, double-blind, multicentre, phase 3 trial conducted in 215 centres in 28 countries. Eligible patients were patients aged 18 … Witryna24 sty 2024 · 同时在2024年的esmo大会上也有两项同样进行高危肾癌辅助治疗的研究,immotion010研究和prosper研究,但结果都是阴性。 因此未来肾癌高危术后的辅助治疗一定会是一个亮点,同时也要重视患者的筛选和如何平衡毒副作用与获益之间的关系。 bird lane tiptree